244 related articles for article (PubMed ID: 24131925)
1. The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Wang Q; Weisberg E; Zhao JJ
Cell Cycle; 2013 Dec; 12(23):3589-93. PubMed ID: 24131925
[TBL] [Abstract][Full Text] [Related]
2. Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
Wang Q; Von T; Bronson R; Ruan M; Mu W; Huang A; Maira SM; Zhao JJ
Genes Dev; 2013 Jul; 27(14):1568-80. PubMed ID: 23873941
[TBL] [Abstract][Full Text] [Related]
3. Hamartoma-like lesions in the mouse retina: an animal model of
Tachibana N; Touahri Y; Dixit R; David LA; Adnani L; Cantrup R; Aavani T; Wong RO; Logan C; Kurek KC; Schuurmans C
Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29716894
[No Abstract] [Full Text] [Related]
4. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.
Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
[TBL] [Abstract][Full Text] [Related]
5. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
6. PTEN hamartoma tumor syndromes.
Blumenthal GM; Dennis PA
Eur J Hum Genet; 2008 Nov; 16(11):1289-300. PubMed ID: 18781191
[TBL] [Abstract][Full Text] [Related]
7. PI3K pathway dependencies in endometrioid endometrial cancer cell lines.
Weigelt B; Warne PH; Lambros MB; Reis-Filho JS; Downward J
Clin Cancer Res; 2013 Jul; 19(13):3533-44. PubMed ID: 23674493
[TBL] [Abstract][Full Text] [Related]
8. Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.
Schmidt JW; Wehde BL; Sakamoto K; Triplett AA; Anderson SM; Tsichlis PN; Leone G; Wagner KU
Mol Cell Biol; 2014 Apr; 34(7):1363-77. PubMed ID: 24469394
[TBL] [Abstract][Full Text] [Related]
9. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
10. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
11. Regulation of CD38 expression in human airway smooth muscle cells: role of class I phosphatidylinositol 3 kinases.
Jude JA; Tirumurugaan KG; Kang BN; Panettieri RA; Walseth TF; Kannan MS
Am J Respir Cell Mol Biol; 2012 Oct; 47(4):427-35. PubMed ID: 22556157
[TBL] [Abstract][Full Text] [Related]
12. Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1.
Berglund FM; Weerasinghe NR; Davidson L; Lim JC; Eickholt BJ; Leslie NR
Oncogene; 2013 Sep; 32(37):4417-26. PubMed ID: 23085752
[TBL] [Abstract][Full Text] [Related]
13. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
[TBL] [Abstract][Full Text] [Related]
14. Genodermatosis Affecting the Skin and Mucosa of the Head and Neck: Clinicopathologic, Genetic, and Molecular Aspect--PTEN-Hamartoma Tumor Syndrome/Cowden Syndrome.
Nosé V
Head Neck Pathol; 2016 Jun; 10(2):131-8. PubMed ID: 26975628
[TBL] [Abstract][Full Text] [Related]
15. PTEN hamartoma tumour syndrome: case report based on data from the Iranian hereditary colorectal cancer registry and literature review.
Rahmatinejad Z; Goshayeshi L; Bergquist R; Goshayeshi L; Golabpour A; Hoseini B
Diagn Pathol; 2023 Apr; 18(1):43. PubMed ID: 37016356
[TBL] [Abstract][Full Text] [Related]
16. Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome".
Galatola M; Paparo L; Duraturo F; Turano M; Rossi GB; Izzo P; De Rosa M
BMC Med Genet; 2012 Apr; 13():28. PubMed ID: 22520842
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease.
Torices L; Mingo J; Rodríguez-Escudero I; Fernández-Acero T; Luna S; Nunes-Xavier CE; López JI; Mercadillo F; Currás M; Urioste M; Molina M; Cid VJ; Pulido R
Eur J Hum Genet; 2023 May; 31(5):568-577. PubMed ID: 36543932
[TBL] [Abstract][Full Text] [Related]
18. Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer.
Zhang C; Xu B; Liu P
Tumour Biol; 2016 Nov; 37(11):14831-14839. PubMed ID: 27639383
[TBL] [Abstract][Full Text] [Related]
19. Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss.
Cizmecioglu O; Ni J; Xie S; Zhao JJ; Roberts TM
Elife; 2016 Oct; 5():. PubMed ID: 27700986
[TBL] [Abstract][Full Text] [Related]
20. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome.
Bubien V; Bonnet F; Brouste V; Hoppe S; Barouk-Simonet E; David A; Edery P; Bottani A; Layet V; Caron O; Gilbert-Dussardier B; Delnatte C; Dugast C; Fricker JP; Bonneau D; Sevenet N; Longy M; Caux F;
J Med Genet; 2013 Apr; 50(4):255-63. PubMed ID: 23335809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
